Histogen
Histogen Inc. is a clinical-stage regenerative medicine company based in San Diego, California. Established in 2007, it focuses on developing therapies that utilize products derived from cells cultured in environments that simulate embryonic conditions. The company’s offerings include human multipotent cell conditioned media, human extracellular matrix materials, and hair-stimulating complexes. Histogen's proprietary technology encourages the production of essential proteins and growth factors by newborn cells in bioreactors designed to mimic embryonic conditions. The company aims to create stem cell-free biologic products, including candidates for joint cartilage and spinal disc repair. Additionally, Histogen is working on a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases, aligning with its mission to promote the body’s natural repair processes.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.